We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DMRC:NASDAQDigimarc Corporation Analysis

Data as of 2026-06-18 - not real-time

$9.58

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Digimarc (DMRC) is trading at $9.58, well below its 20‑day SMA of $12.88 but just above the 200‑day SMA of $7.99, indicating a short‑term pullback within a longer‑term uptrend. The RSI of 38 suggests the stock is approaching oversold territory, yet the MACD remains bearish with the line below the signal, and volume is trending down, adding pressure on the near‑term price. Volatility is extreme at 130% over the past 30 days and beta exceeds 2.0, reflecting a highly speculative profile that aligns with the “Extreme Greed” market sentiment. A discounted cash‑flow model values the company at roughly $2.20 per share, implying a substantial overvaluation relative to the current market price.
Fundamentally, DMRC posted a 19% revenue decline, negative operating and profit margins, and a trailing EPS of –$1.26, while free cash flow turned positive at $3.38 M. The recent appointment of veteran CEO Paul Carreiro and the launch of an agent‑native provenance platform for AI ecosystems provide a clear growth narrative, but the balance sheet remains thin with $5 M of debt and a debt‑to‑equity ratio above 14, underscoring ongoing financial fragility.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 5/10

Key Factors

  • Bearish MACD histogram
  • Price below 20‑day SMA
  • Decreasing trading volume

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • New CEO with growth‑focused background
  • Launch of AI‑centric provenance platform
  • Potential upside if revenue turnaround materializes

Long Term

> 3 years
Cautious
Model confidence: 4/10

Key Factors

  • Sustained operating losses and negative EPS
  • Significant overvaluation versus DCF fair value
  • High beta and extreme price volatility

Key Metrics & Analysis

Financial Health

Revenue Growth-19.10%
Profit Margin-85.75%
P/E Ratio-28.2
ROE-65.52%
ROA-27.16%
Debt/Equity14.69
P/B Ratio6.2
Op. Cash Flow$-8140000
Free Cash Flow$3.4M
Industry P/E38.1

Technical Analysis

TrendBullish
RSI38.4
Support$9.27
Resistance$17.47
MA 20$12.88
MA 50$9.95
MA 200$8.00
MACDBearish
VolumeDecreasing
Fear & Greed Index92.14

Valuation

Fair Value$2.22
Target Price$11.50
Upside/Downside20.04%
GradeOvervalued
TypeBlend

Risk Assessment

Beta2.61
Volatility129.74%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.